Publicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (285)

2024

  1. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

    The Lancet, Vol. 404, Núm. 10459, pp. 1227-1239

  2. A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

    Clinical Cancer Research, Vol. 30, Núm. 11, pp. 2377-2383

  3. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

  4. Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study

    Journal of Thoracic Oncology, Vol. 19, Núm. 2, pp. 285-296

  5. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

  6. Canakinumab as Adjuvant Therapy in Patients With Completely Resected Non-Small-Cell Lung Cancer: Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 2, pp. 180-191

  7. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas

    International Journal of Gynecological Cancer, Vol. 34, Núm. 10, pp. 1499-1521

  8. Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

    Blood, Vol. 144, Núm. 3, pp. 334-338

  9. Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases

    Lung Cancer, Vol. 188

  10. Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

    European Urology

  11. NTRK gene fusion testing and management in lung cancer

    Cancer Treatment Reviews, Vol. 127

  12. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

    Annals of Oncology, Vol. 35, Núm. 11, pp. 1026-1038

  13. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma

    Journal of Hematology and Oncology, Vol. 17, Núm. 1

  14. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 25, Núm. 5, pp. 572-587

  15. Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma

    European Journal of Cancer, Vol. 207

  16. The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program

    HemaSphere, Vol. 8, Núm. 6

2023

  1. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

    Journal of Thoracic Oncology, Vol. 18, Núm. 12, pp. 1731-1742

  2. Changes in Liver Lipidomic Profile in G2019S-LRRK2 Mouse Model of Parkinson’s Disease

    Cells, Vol. 12, Núm. 5

  3. Clinical, methodology, and patient/carer expert advice in pediatric drug development by conect4children

    Clinical and Translational Science, Vol. 16, Núm. 3, pp. 478-488

  4. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis

    Future Oncology, Vol. 19, Núm. 12, pp. 819-828